期刊文献+

脑胶质瘤组织肿瘤浸润性树突状细胞及其分子标志物MHC-Ⅱ与CD54的表达情况及意义 被引量:4

Status of tumor infiltrating dendritic cells in glioma tissue and the expression levels of MHC-Ⅱ and CD54 in such cells
原文传递
导出
摘要 目的探讨脑胶质瘤组织肿瘤浸润性树突状细胞(tumor infiltrating dendritic cells,TIDC)及其分子标志物MHC-Ⅱ、CD54表达情况及意义。方法选择宁波市李惠利医院神经外科2013年1月—2017年6月脑胶质瘤组织标本70例作为脑胶质瘤组织组,正常脑组织标本70例作为正常脑组织组,脑胶质瘤组根据WHO病理分级分为低级别脑胶质瘤组(Ⅰ级+Ⅱ级)19例和高级别脑胶质瘤组(Ⅲ级+Ⅳ级)51例。采用免疫组化法测定脑胶质瘤组织TIDC数量和正常脑组织中树突状细胞(dendritic cells,DC)数量,采用流式细胞仪检测脑胶质瘤组织TIDC和正常脑组织中DC膜表面MHC-Ⅱ、CD54表达。结果细胞核出现棕褐色颗粒为S-100阳性染色的DC细胞。脑胶质瘤组织中TIDC数量低于正常脑组织中DC数量(P<0.05);高级别脑胶质瘤组织中TIDC数量低于低级别脑胶质瘤组织中TIDC数量(P<0.05)。脑胶质瘤组织TIDC膜表面MHC-Ⅱ、CD54表达量低于正常脑组织中DC膜表面MHC-Ⅱ、CD54表达(P<0.05)。高级别脑胶质瘤组织TIDC膜表面MHC-Ⅱ、CD54表达量低于低级别脑胶质瘤组织TIDC膜表面MHC-Ⅱ、CD54表达量(P<0.05)。结论脑胶质瘤组织中TIDC细胞少于正常脑组织中DC细胞,随着脑胶质瘤级别的升高,TIDC细胞浸润数目减少,脑胶质瘤存在抗原提呈功能缺失或降低。 Objective To investigate the number of tumor infiltrating dendritic cells in glioma tissue and the expression levels of MHC-Ⅱ and CD54 in such cells. Methods Total 70 cases of glioma tissue specimens were taken as glioma tis- sue group, and 70 cases of normal brain tissue specimens were taken as normal brain tissue group in Ningbo Lihuili Hos- pital from January, 2013 to June, 2017. The glioma group was divided into low grade glioma group (grade Ⅰ + grade Ⅱ , 19 cases) and high grade glioma group (grade Ⅲ + Ⅳ, 51 cases) according to WHO pathological grade. The num- ber of TIDCs in brain glioma tissues and the number of dendritic cells (DCs) in normal brain tissues were measured by immunohistochemistry. The expressions of MHC-Ⅱ and CD54 on the surface of DCs were detected by flow eytometry in TIDC and normal brain tissues. Results The nuclei appear as brown particles were S-100 positive staining DC cells. The number of TIDCs in glioma tissue was lower than that in normal brain tissue ( P 〈 0.05 ). The number of TlDCs in high-grade gliomas was lower than that in low-grade gliomas (P 〈 0.05). The expression of MHC-Ⅱ and CD54 on the surface of TIBC was lower than that in normal brain tissue ( P 〈 O. 05 ). The expression of MHC-Ⅱ and CD54 on the TIDC membrane in high-grade gliomas tissue was higher than that in the low-grade glioma tissue ( P 〈 0.05 ). Conclusion TIDC cells in brain glioma tissue is less than normal brain tissue DC cells. With the increase of glioma grade, TIDC cell infiltration decreases. The presence of antigenic presentation in the glioma is absent or decreased.
作者 沈罡 沈宏 胡未伟 朱光耀 王波定 孙成丰 SHEN Gang, SHEN Hong, HU Wei-wei, et al(Department of Neurosurgery, Ningbo Lihuili East Hospital, Ningbo, Zhejiang 315040, Chin)
出处 《中华全科医学》 2018年第4期552-554,653,共4页 Chinese Journal of General Practice
基金 浙江省自然科学基金(LY17H16001) 宁波市自然基金科技计划项目(2012A610195)
关键词 脑胶质瘤 肿瘤浸润性树突状细胞 MHC-Ⅱ CD54 Glioma Tumor-infiltrating dendritic cells MHC-Ⅱ CD54
  • 相关文献

参考文献6

二级参考文献109

  • 1连利娟,林巧稚.妇科肿瘤学[M].北京:人民卫生出版社,2006,405-406. 被引量:28
  • 2Ashrafian LA,Antonova IB,Aleshikova OI,et al.Comprehensive eval-uation of neoadjuvant chemotherapy for locally-advanced cervical car-cinoma(stage IIb-IIIb)[J].Vopr Onko,2009,55(4):463-470. 被引量:1
  • 3BalducciM,D ’ AgostinoGR,ManfridaS,et al.Radiotherapynad concomi-tant temozolomide during the first and lastweeksin high gradegliomas:long-term analysis o faphase II study [J].J Neurooncol,2010,97⑴:95-100. 被引量:1
  • 4马磊,王韵一,姬英,常占国,赵旭林,贺利民.胃癌、贲门癌患者外周血T淋巴细胞AgNORs检测的临床意义[J].临床医学,2007,27(9):81-82. 被引量:3
  • 5McNutt M. Cancer immunotherapy[J]. Science, 2013, 342: 1432-1433. 被引量:1
  • 6Schreiber R D, Old L J, Smyth M J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570. 被引量:1
  • 7Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: Tumor-targeting monoclonal antibodies in cancer therapy[J]. Oneoimmunology, 2014, 3 (1): e27048-1-20. 被引量:1
  • 8Li S, Sehmitz K R, Jeffrey P D, et al. Structural basis for inhibition of the epidermal growth factor receptor by eetuximab[J]. Cancer Cell, 2005, 7(4): 301-311. 被引量:1
  • 9van Cutsem E, Kohne C H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. The New England Journal of Medicine, 2009, 360(14):1408-1417. 被引量:1
  • 10Kuenen B, Witteveen P O, Ruijter R, et al. A phase i pharmacologic study of neeitumumab (imc-llf8), a fully human iggl monoclonal antibody directed against egfr in patients with advanced solid malignancies[J]. Clinical Cancer Research, 2010, 16(6): 1915-1923. 被引量:1

共引文献27

同被引文献17

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部